 KING OF PRUSSIA, Pa., May 6, 2021 PRNewswire -- Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure NASDAQ: QURE for etranacogene dezaparvovec AMT-061, a novel gene therapy for the treatment of hemophilia B. 